WuXi PharmaTech Announces Fourth Quarter and Full Year 20...(2313 27279 (35148) Basic earni...)

Basic earnings (loss) per ADS 0.20 0.08 0.56 (1.18)

Diluted earnings (loss) per ADS 0.17 0.07 0.42 (1.18)

Number of shares used in

calculation (Note 2):

Weighted average ADS

outstanding - basic 61,528,350 28,882,500 38,506,277 29,813,325

Weighted average ADS

outstanding - diluted 72,544,322 35,022,194 64,393,436 29,813,325

Note 2: One (1) ADS equals eight (8) ordinary shares

WUXI PHARMATECH (CAYMAN) INC.

RECONCILIATION OF NON-GAAP TO GAAP

(in thousands of US Dollars, except per ADS data)

(Unaudited)

Three Months Ended Year Ended

December 31, December 31,

2007 2006 2007 2006

GAAP net income 12,131 3,968 33,903 8,853

Add: Share-based compensation

expenses 4,454 2,493 10,715 8,409

Non-GAAP net income 16,585 6,461 44,618 17,262

Income (loss) attributable

to holders of ADS

(Non-GAAP):

Basic 16,585 3,766 31,477 (26,739)

Diluted 16,585 3,766 37,994 (26,739)

Basic earnings (loss) per

ADS (Non-GAAP) 0.27 0.13 0.82 (0.90)

Diluted earnings (loss) per

ADS (Non-GAAP) 0.23 0.11 0.59 (0.90)

Weighted average ADS

outstanding - basic 61,528,350 28,882,500 38,506,277 29,813,325

Weighted average ADS

outstanding - diluted 72,544,322 35,022,194 64,393,436 29,813,325

For more information, please contact
'/>"/>